HOME >> BIOLOGY >> NEWS
Blood test may help signal tumor's remission, return in throat cancer patients

A blood test that detects proteins commonly released by a growing tumor could one day become a useful tool for monitoring the effectiveness of chemotherapy and radiation treatment in people with advanced throat cancer, according to a study published in the June 1, 2007, issue of Clinical Cancer Research. Scientists in the National Institute on Deafness and Other Communication Disorders (NIDCD) and National Cancer Institute (NCI), two of the National Institutes of Health (NIH), in collaboration with researchers of the University of Michigan, found that throat cancer patients who showed a decline in several cancer-related proteins following chemotherapy and radiation treatment were more likely to remain in remission, while those who experienced a large rise over time in those proteins frequently exhibited a return of throat cancer. The findings could help lead to the development of a blood test that enables doctors to detect the recurrence of throat cancer early on, when there is still time to pursue a second line of treatment, such as surgery or drug therapy.

Cancers of the head and neck are insidious because surgical removal of the tumor can severely impair a persons ability to talk and to swallow, said NIDCD Director, James F. Battey, Jr., M.D., Ph.D. A blood test that enables doctors to closely monitor a patients rehabilitation while sparing the patients voice, speech, and swallowing ability is an excellent example of the predictive, preemptive, and personalized approach to medicine that the NIH strives for.

Roughly 20 years ago, the primary method for treating throat cancer was to surgically remove the tumor. Because this treatment can severely impair a patients quality of life by damaging voice, speech, and swallowing, in many cases physicians and their patients are now opting for a combination of chemotherapy and radiation as a first line of treatment. However, there is no way to predict which patients will respond well to this tr
'"/>

Contact: Patricia Blessing
blessinp@mail.nih.gov
301-496-7243
NIH/National Institute on Deafness and Other Communication Disorders
1-Jun-2007


Page: 1 2 3 4

Related biology news :

1. Blood sugars manufacture limited by building blocks supply
2. Bloods clotting cells harbor ticking time bombs, finding may help extend blood supply
3. Blood tests may be possible for mental health conditions
4. Cord Blood Registry achieves industry-leading stem cell recovery with new automation technology
5. Blood test predicts cardiac events and death in heart patients
6. Blood clot fibers more elastic than spiders web
7. Blood-compatible nanoscale materials possible using heparin
8. Blood pressure medication may revolutionize treatment of Marfan syndrome
9. Blood levels of suspected carcinogen vary by race, ethnicity
10. Blood conservation strategies take center stage at Emory University Hospital forum
11. Blood test for colon cancer risk to be goal of Hopkins project

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... ... Regenative Labs has received approval from the Centers for Medicare & Medicaid Services ... jelly allografts to be assigned a Q code and be approved for application directly ... allograft product to be recognized as a 361 HCT/P by CMS regulated under 21CFR ...
(Date:7/31/2020)... SAN FRANCISCO (PRWEB) , ... July 30, 2020 ... ... Therapeutics’ maturing prescription digital therapeutics product portfolio with a near term focus on ... diverse biotech and pharma commercialization experience across multiple therapeutic areas and classes. As ...
(Date:7/18/2020)... , ... July 17, 2020 , ... Commercial launch readiness ... pharma’s ability to discover a COVID cure or vaccine, the global economic downturn will ... price pressure is not going away and capturing full value from every product launch ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... reliable, solid-state radar transmitter systems that can be configured to drive Klystrons, TWTs, ... controller that can drive one or two switches in a push-pull configuration; yielding ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the ... the history of eSource, the reasons it did not take off as quickly as ... source, the industry is moving towards capturing data electronically for clinical trials and then ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from ... Sr. Manager Regulatory Solutions, in a one hour live webinar on Thursday, ... body in China for drugs and medical devices. Specifically, for medical devices, the NMPA ...
(Date:7/18/2020)... ... July 16, 2020 , ... Medial EarlySign , a ... prevention of high-burden diseases, and Centric Consulting, a business and technology consulting firm, ... existing data in order to identify and prioritize patients for care. , Combining ...
Breaking Biology Technology:
Cached News: